Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Treatment options for high-risk AML

Nigel Russell • 16 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Antibodies Clofarabine Cytarabine Daunorubicin Fludarabine G-CSF Idarubicin Venetoclax
AML17

Nigel Russell, MD, Guy’s Hospital NHS Trust, London, UK, talks on attempts to improve treatment options for younger patients with high-risk acute myeloid leukemia (AML). Specifically discussed is the UK NCRI AML17 trial (ISRCTN55675535), comparing FLAG-Ida and daunorubicin with clofarabine for high-risk AML. Prof. Russell highlights the importance of early recognition of high-risk disease and reveals that optimizing induction and pre-stem cell transplant treatment allows more patients to get to transplant in remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Nigel Russell

AML19: FLAG-Ida vs CPX-351 in patients with AML with adverse risk cytogenetics
1:02
AML19: FLAG-Ida vs CPX-351 in patients with AML with adverse risk cytogenetics
Nigel Russell • 10 Jun 2023
Gemtuzumab-based induction chemotherapy with midostaurin in FLT3-mutated AML
1:21
Gemtuzumab-based induction chemotherapy with midostaurin in FLT3-mutated AML
Nigel Russell • 10 Jun 2023
AML19 update: improvement in OS in patients with NPM1-mutated AML treated with FLAG-Ida-GO
1:52
AML19 update: improvement in OS in patients with NPM1-mutated AML treated with FLAG-Ida-GO
Nigel Russell • 10 Jun 2023
AML19 trial: FLAG-Ida-GO vs DA-GO in standard-risk AML and FLAG-Ida vs CPX-351 in high-risk AML
3:26
AML19 trial: FLAG-Ida-GO vs DA-GO in standard-risk AML and FLAG-Ida vs CPX-351 in high-risk AML
Nigel Russell • 12 Dec 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals